The Frequency and Contributing Factors of Pulmonary Infections in Lung Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors - Top-Institutions - MDSpire

The Frequency and Contributing Factors of Pulmonary Infections in Lung Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors

  • By

  • Haixia Yang

  • Yaxuan Han

  • Xiaosha Zhou

  • Jianying Li

  • Yanjun Zhao

  • Shanshan Zhang

  • December 15, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Pulmonology
    • Infectious Diseases

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Pulmonology
    • Immunology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Pulmonology
    • Infectious Diseases

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Pulmonology
    • Medical Oncology
    • Infectious Diseases

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Pulmonology
    • Immunology

Original Source(s)

The Frequency and Contributing Factors of Pulmonary Infections in Lung Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors

  • by Haixia Yang, Yaxuan Han, Xiaosha Zhou, Jianying Li, Yanjun Zhao, Shanshan Zhang

  • December 15, 2025

Related Content

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence

Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report